Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Leveraging CRISPR/Cas9 for optimized adoptive T cell therapies: From molecular engineering to clinical manufacturing.

Biochemical and biophysical research communications·2026

Same author

Corrigendum to: Deep Learning-Based Protein Half Life Prediction for Identifying Rate Limiting Enzymes in Metabolic Pathways to Alleviate Bottleneck Reactions.

Journal of microbiology and biotechnology·2026

Same author

Deep Learning-Based Protein Half-Life Prediction for Identifying Rate-Limiting Enzymes in Metabolic Pathways to Alleviate Bottleneck Reactions.

Journal of microbiology and biotechnology·2026

Same author

A20 mRNA therapeutics ameliorate systemic sclerosis by suppressing TRAF-6/NF-KB signaling and DREAM expression and exerting antifibrotic effects.

Frontiers in immunology·2025

Same author

Genetic "expiry-date" circuits control lifespan of synthetic scavenger bacteria for safe bioremediation.

Nucleic acids research·2025

Same author

A review on computational models for predicting protein solubility.

Journal of microbiology (Seoul, Korea)·2025

Search research articles

Related Experiment Video

Updated: Jun 24, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Engineered T Cell Receptor for Cancer Immunotherapy.

So Won Lee¹, Hyang-Mi Lee¹

¹College of Pharmacy, Dongduk Women's University, Seoul 02748, Republic of Korea.

Biomolecules & Therapeutics

|June 6, 2024

Summary

Engineered T cell therapies, including T cell receptor (TCR)-T cells, show promise for treating solid tumors. This review focuses on TCR-T cell therapy, exploring its characteristics and clinical applications beyond blood cancers.

Keywords:

CAR-T cell Cancer immunotherapy Solid tumor TCR-T cell

More Related Videos

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: Jun 24, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Area of Science:

Immunology and Oncology
Cellular Therapy
Biotechnology

Background:

Cancer immunotherapy encompasses various strategies like immune-modulating antibodies, cancer vaccines, and adoptive T cell transfer.
T cells are crucial due to their tumor cell cytotoxicity and specific receptor binding.
Genetically engineered T cells, such as chimeric antigen receptor-T cells (CAR-T) and T cell receptor (TCR)-T cells, enhance therapeutic specificity and efficacy.

Purpose of the Study:

To review anti-tumor T cell therapies, with a specific focus on engineered T cell receptor (TCR)-T cell therapy.
To outline the characteristics of TCR-T cell therapy.
To discuss the clinical application of TCR-T cell therapy in non-hematological malignancies.

Main Methods:

Review of existing literature on T cell-based cancer immunotherapies.
Analysis of the mechanisms and properties of engineered T cell therapies, particularly TCR-T cells.
Examination of clinical data and applications of TCR-T cell therapy in solid tumors.

Main Results:

Adoptive cell transfer of CAR-T cells has demonstrated success in treating hematological malignancies.
TCR-T cell therapy involves genetically modifying T cells to express specific TCRs targeting tumor-associated antigens.
This approach aims to extend the benefits of T cell therapy to solid tumors.

Conclusions:

Engineered TCR-T cell therapy represents a promising strategy for expanding T cell therapy to solid tumors.
Understanding the characteristics and clinical applications of TCR-T cells is crucial for advancing their use in non-hematological malignancies.
TCR-T cell therapy offers enhanced specificity and effectiveness for targeting solid tumors.